Literature DB >> 22220936

BCNU-associated pneumonitis: portrait of a toxicity.

Brian G Till1, David K Madtes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22220936     DOI： 10.3109/10428194.2011.654341

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

1.  Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation.

Authors:  Andrzej Frankiewicz; Maria Saduś-Wojciechowska; Jacek Najda; Tomasz Czerw; Włodzimierz Mendrek; Małgorzata Sobczyk-Kruszelnicka; Katarzyna Soska; Małgorzata Ociepa; Jerzy Hołowiecki; Sebastian Giebel
Journal:  Contemp Oncol (Pozn)       Date:  2018-06-30

2.  BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.

Authors:  Logan Hahn; Hyun Lim; Tanner Dusyk; Waleed Sabry; Mohamed Elemary; Julie Stakiw; Pat Danyluk; Mark Bosch
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

3.  Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Authors:  Maurizio Musso; Giuseppe Messina; Nicola Di Renzo; Paolo Di Carlo; Umberto Vitolo; Renato Scalone; Gianpaolo Marcacci; Potito R Scalzulli; Tiziana Moscato; Rossella Matera; Alessandra Crescimanno; Stella Santarone; Enrico Orciuolo; Anxur Merenda; Vincenzo Pavone; Domenico Pastore; Daniela Donnarumma; Angelo M Carella; Chiara Ciochetto; Nicola Cascavilla; Anna Mele; Francesco Lanza; Massimo Di Nicola; Erminio Bonizzoni; Antonello Pinto
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

4.  Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients.

Authors:  Jung Yoon Choi; Hyoung Jin Kang; Hong Yul An; Kyung Taek Hong; Hee Young Shin
Journal:  Int J Hematol       Date:  2020-03-26       Impact factor: 2.490
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.